Rapastinel: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •2 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 8 community reports
- •1 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Administration Route | All clinical trials used single-dose intravenous (IV) infusion. The phase 2 trial used doses of 1, 5, 10, or 30 mg/kg IV. Phase 3 trials used 225 mg or 450 mg IV weekly. | The small number of community users attempting rapastinel use subcutaneous injection or intranasal routes, neither of which was studied clinically. IV infusion is impractical for self-administration. | high Route conversion from IV to SubQ or intranasal fundamentally alters pharmacokinetics. Rapastinel's bioavailability via non-IV routes is unknown and may be very low as a tetrapeptide. |
| Clinical Outcome | Phase 2 trials showed promising rapid-onset antidepressant effects within 2 hours of IV dosing. However, three phase 3 trials failed to differentiate from placebo (announced March 2019), leading to discontinuation of development. | A small number of community members experimented with rapastinel based on the phase 2 data, often unaware of or dismissing the phase 3 failures. Community reports are very sparse and inconsistent. | high The phase 3 failure is a critical consideration. Rapastinel did not demonstrate efficacy in well-controlled phase 3 trials despite promising phase 2 results. Community use is based on data from trials that ultimately failed to replicate. |
| Dosing Translation | Effective phase 2 dose was 5-10 mg/kg IV (350-700 mg for a 70 kg person). Phase 3 used 225 mg and 450 mg IV weekly. | Community experiments use drastically lower doses (1-5 mg total), reflecting both cost constraints and safety caution. These doses are orders of magnitude lower than clinical doses. | high Community doses are a tiny fraction of clinical doses. At such low doses via non-IV routes, it is highly unlikely that pharmacologically relevant plasma concentrations are achieved. |
Compare these community approaches with published research findings.
Community Protocols
Low-Dose IV-Mimicking Protocol
Niche- Route
- Subcutaneous
- Dose
- 1-5 mg
- Frequency
- Once weekly
- Duration
- 4-8 weeks
Adapted from clinical IV dosing; community uses SubQ as a practical alternative to IV infusion
Intranasal Experimental Protocol
Niche- Route
- Intranasal
- Dose
- 1-3 mg
- Frequency
- 1-2 times weekly
- Duration
- 4-6 weeks
Some users attempt intranasal delivery for brain penetration; no data supports this route for rapastinel
Stacking Patterns
Rapastinel + Semax Cognitive Stack
NicheTheoretical combination of NMDA modulation (rapastinel) with BDNF upregulation (Semax) for synergistic neuroplasticity effects
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 8+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Nootropics|Rapastinel/GLYX-13 discussion threads and experience reports(accessed 2026-02-16)
- Reddit r/Peptides|GLYX-13 protocol discussions(accessed 2026-02-16)
- Nootropics On Reddit (Tumblr archive)|Important Post On Rapastinel (GLYX-13) antidepressant with neuroplasticity properties(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Rapastinel (GLYX-13). The information below is gathered from nootropic forums and Reddit communities. This is not clinical evidence and should not be used as medical guidance.
Rapastinel has very limited community usage. Its development was discontinued after three phase 3 trials failed to differentiate from placebo for major depressive disorder in 2019. Community interest is primarily theoretical, based on its unique mechanism of action as an NMDA receptor partial agonist that enhances neuroplasticity without ketamine-like side effects.
Understanding Protocol Divergence#
Failed Phase 3 Context#
The most critical consideration for rapastinel is that its clinical development was discontinued after phase 3 failure. While phase 2 data was promising enough to earn FDA Breakthrough Therapy designation, the drug could not demonstrate efficacy in larger, well-controlled trials. This fundamentally undermines the evidence base for community use.
Route and Dose Mismatch#
The few community members who have experimented with rapastinel face a significant practical problem: clinical trials used IV infusion at doses of 225-450 mg, while community use involves subcutaneous injection at 1-5 mg. This represents both a route change (with unknown bioavailability for SubQ) and a dose reduction of roughly 100-fold. It is highly unlikely that these community protocols achieve pharmacologically relevant effects.
Commonly Reported Outcomes#
Community reports for rapastinel are extremely sparse and inconsistent:
- Mood effects: Some users report subtle mood improvements, but these are difficult to distinguish from placebo given the phase 3 failure context
- No effect: Many users report no noticeable effects, consistent with the dose and route limitations
- Well-tolerated: The few reports available generally note good tolerability without significant side effects
Important Caveats#
- Phase 3 clinical trials failed to demonstrate efficacy
- Community doses and routes are fundamentally different from clinical protocols
- Very few community reports exist
- The compound is difficult to obtain as a research chemical
- Self-treatment of depression with unproven compounds carries serious risks
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Rapastinel
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.